Zobrazeno 1 - 10 of 304 pro vyhledávání: '"Fainberg U"'
1
Akademický článek
Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk.
Autor: Westerink J; Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands., Matthiessen KS; Novo Nordisk A/S, Søborg, Denmark., Nuhoho S; Novo Nordisk A/S, Søborg, Denmark., Fainberg U; Novo Nordisk A/S, Søborg, Denmark., Lyng Wolden M; Novo Nordisk A/S, Søborg, Denmark., Østergaard HB; Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands., Visseren F; Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands., Sattar N; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, U.K.
Publikováno v: Diabetes care [Diabetes Care] 2022 May 01; Vol. 45 (5), pp. 1211-1218.
Zobrazit plný text záznamu
2
Akademický článek
Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i.
Autor: Blonde L; Ochsner Diabetes Clinical Research Unit, Frank Riddick Diabetes Institute, Department of Endocrinology, Ochsner Medical Center, New Orleans, Louisiana, USA., Fainberg U; Novo Nordisk A/S, Søborg, Denmark., Kaltoft MS; Novo Nordisk A/S, Søborg, Denmark., Mosenzon O; Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., Ramesh C; Novo Nordisk, Bangalore, India., Rea R; Hospital de Clínicas, Universidade Federal do Paraná (SEMPR), Curitiba, Brazil.
Publikováno v: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2021 Oct; Vol. 23 (10), pp. 2234-2241. Date of Electronic Publication: 2021 Jul 08.
Zobrazit plný text záznamu
3
Akademický článek
Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide.
Autor: Verma S; St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada., Fainberg U; Novo Nordisk A/S, Søborg, Denmark., Husain M; Department of Medicine, Ted Rogers Centre for Heart Research, Toronto General Hospital Research Institute, University of Toronto, Toronto, Ontario, Canada., Rasmussen S; Novo Nordisk A/S, Søborg, Denmark., Rydén L; Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden., Ripa MS; Novo Nordisk A/S, Søborg, Denmark., Buse JB; University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Publikováno v: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2021 Jul; Vol. 23 (7), pp. 1677-1680. Date of Electronic Publication: 2021 Mar 18.
Zobrazit plný text záznamu
4
Akademický článek
Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial.
Autor: Blonde L; Ochsner Diabetes Clinical Research Unit, Frank Riddick Diabetes Institute, Department of Endocrinology, Ochsner Medical Center, New Orleans, Louisiana, United States., Belousova L; Almazov National Medical Research Centre, Saint-Petersburg, Russian Federation., Fainberg U; Novo Nordisk A/S, Søborg, Denmark., Garcia-Hernandez PA; Endocrinology Service, University Hospital, Monterrey, Mexico., Jain SM; Endocrinology, TOTALL Diabetes Hormone Institute, Indore, Madhya Pradesh, India., Kaltoft MS; Novo Nordisk A/S, Søborg, Denmark., Mosenzon O; Diabetes Unit, Division of Internal Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel., Nafach J; Dubai Diabetes Center, Dubai Health Authority, Dubai, United Arab Emirates., Palle MS; Novo Nordisk A/S, Søborg, Denmark., Rea R; Endocrinology and Metabolism Service (SEMPR), Universidade Federal do Paraná, Curitiba, Brazil.
Publikováno v: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2020 Jun; Vol. 22 (6), pp. 929-937. Date of Electronic Publication: 2020 Feb 14.
Zobrazit plný text záznamu
5
Akademický článek
청년 2형당뇨병의 통합적 관리 전략.
Autor: Seo, Mi-Hae1, Kwak, Soo Heon2 shkwak@snu.ac.kr
Publikováno v: Journal of Korean Diabetes. Sep2024, Vol. 25 Issue 3, p150-156. 7p.
Zobrazit plný text záznamu
6
Akademický článek
Polypeptides-Based Nanocarriers in Tumor Therapy.
Autor: You, Juhua1,2 (AUTHOR), Guo, Yifei1,2 (AUTHOR) yguo@implad.ac.cn, Dong, Zhengqi1,2 (AUTHOR) yguo@implad.ac.cn
Publikováno v: Pharmaceutics. Sep2024, Vol. 16 Issue 9, p1192. 34p.
Zobrazit plný text záznamu
7
Akademický článek
深圳市某三级甲等医院中药饮片处方药味调查 及影响因素分析.
Autor: 李方园1 lifangyuan89@gzucm.edu.cn, 唐志芳1, 陈佳美1, 梅全喜1, 邱绿琴1 qiulvqin@szbazyy.net
Publikováno v: Evaluation & Analysis of Drug-Use in Hospitals of China. 2024, Vol. 24 Issue 9, p1132-1135. 4p.
Zobrazit plný text záznamu
8
Akademický článek
Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Overweight/Obese and/or T2DM Adolescents: A Meta-analysis Based on Randomized Controlled Trials.
Autor: Min Dai1, Senjie Dai1, Lihu Gu2, Zhiyi Xiang3, Anyi Xu3, Siyu Lu1, Yang Yang1, Cong Zhou4 glpobesity@163.com
Publikováno v: Journal of Clinical Research in Pediatric Endocrinology. Sep2024, Vol. 16 Issue 3, p323-333. 11p.
Zobrazit plný text záznamu
9
Akademický článek
Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis.
Autor: Liu, Ligang1 (AUTHOR) liu.10645@osu.edu, Shi, Hekai2 (AUTHOR) 22211280026@m.fudan.edu.cn, Shi, Yufei3 (AUTHOR) yufei_shi@fudan.edu.cn, Wang, Anlin4 (AUTHOR) jordan0309@126.com, Guo, Nuojin5 (AUTHOR) 2233148@tongji.edu.cn, Tao, Heqing6 (AUTHOR) tao_heqing@bjmu.edu.cn, Nahata, Milap C.1,7 (AUTHOR) nahata.1@osu.edu
Publikováno v: Pharmaceuticals (14248247). Jul2024, Vol. 17 Issue 7, p828. 16p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje